Standard usage and dosage of ponatinib and dosage adjustment recommendations for different patients

Ponatinib (Ponatinib) is an oral multi-target tyrosine kinase inhibitor (TKI), mainly used to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (Ph+ ALL), especially suitable for patients who are resistant to other TKIs or have T315I mutations. Standard adult usage is 30mg or 45mg taken orally once a day. The tablet should be swallowed whole without chewing or crushing. It can be taken with or without food.

In clinical practice, the initial dose of ponatinib is usually determined based on the patient's disease severity and tolerance . Standard dosage can effectively inhibit BCR-ABL tyrosine kinase activity, thereby reducing the proliferation rate of leukemia cells. During the medication period, blood routine, liver and kidney function and cardiovascular indicators, as well as molecular responses (BCR-ABLtranscript levels) should be regularly monitored to evaluate efficacy and guide dose adjustment.

For elderly patients, cardiovascular disease or hepatic and renal insufficiency, the initial dose should usually be appropriately reduced to 15–30mg once a day to reduce the risk of vascular events and cumulative drug toxicity. In the event of serious adverse reactions (such as thrombosis, myocardial infarction, or hypertension), the drug should be discontinued and restarted at a reduced dose after symptoms improve, combined with auxiliary drug treatment measures, such as antihypertensive drugs or anticoagulant therapy.

For patients with strong drug resistance or T315I mutation, standard doses or even short-term increments can be considered, but adverse events and hematological indicators need to be strictly monitored. There is insufficient data for children or patients with lower body weight, and the dose should be adjusted individually under the guidance of a specialist. Generally speaking, the principle of using ponatinib is to maintain the efficacy at the lowest effective dose while minimizing toxic and side effects to ensure the safety and long-term sustainability of the treatment.

Reference link:https://www.drugs.com